For patients with advanced clear cell renal cell carcinoma, it will be of utmost importance to recognize the variation in response and type of progression with first-line therapy, the patient’s characteristics and motivations, and the promise of new agents and combinations.
Although community oncologists and hematologists were concerned about loss of income during the COVID-19 pandemic, the loss of in-person patient interaction was cited as the key factor impacting their professional satisfaction.
The American Association for Cancer Research issued a statement today congratulating Robert Califf, MD, on his nomination to be the next FDA commissioner. The association “strongly supports” his return to the agency.
The FDA granted an orphan drug designation to toripalimab for the treatment of patients with esophageal cancer.
Surufatinib demonstrated a comparable health-related quality of life with placebo in patients with advanced neuroendocrine tumors.
The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.
Luis E. Raez, MD, FACP, FCCP, discusses frontline immunotherapeutic options in NSCLC, management strategies for patients with stage III disease, targeted approaches for patients with EGFR- and ALK-positive NSCLC, and how the field of SCLC is navigating newly available therapies.
Florida Cancer Specialists & Research Institute opened its new state-of-the-art Trinity Cancer Center, providing the most advanced and personalized treatments and services for patients with all forms of cancers and blood disorders.
Investigators aim to expand the treatment portfolio with the phase 3 TROPION-LUNG01 trial, which is designed to examine datopotamab deruxtecan vs docetaxel in patients with advanced or metastatic NSCLC without actionable genomic alterations who have previously received platinum-based chemotherapy and immunotherapy.
Concurrent treatment with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia who were receiving lisocabtagene maraleucel led to measurable effects in both CAR+ and endogenous T cells, both of which were linked with improved efficacy.
T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.
Tidutamab was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors of pancreatic, gastrointestinal, lung and undetermined origin.
The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.
The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).
Findings from a new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity, which could help develop a new treatment strategy to benefit patients with melanoma and other cancers.
ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, has demonstrated early signs of biological activity when given as a single agent or in combination with pembrolizumab in patients with advanced solid tumors.
The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.
Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.
Prophylactic octreotide can be safely discontinued in patients with neuroendocrine tumors undergoing operation, as stopping its use has not been shown to increase the rate or duration of carcinoid crisis.
The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.
The FDA has approved ropeginterferon alfa-2b-njft for use as a treatment in patients with polycythemia vera.
The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.
ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys.
The innate cell engager AFM24 showed greater efficacy in eliciting antibody-dependent cellular phagocytosis of EGFR wild-type and KRAS-mutant tumor cells compared with cetuximab.
The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.
